Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Participants With Unresectable Advanced Biliary Tract Carcinoma (BTC)

Next Previous
X
Search
Trial Profile

A Study to Evaluate GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Participants With Unresectable Advanced Biliary Tract Carcinoma (BTC)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Ociperlimab (Primary) ; Tislelizumab (Primary)
  • Indications Biliary cancer; Carcinoma; Cholangiocarcinoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Jan 2024 Results (As of 24 Aug 2023) assessing safety and efficacy of tislelizumab (TIS) and ociperlimab combined with gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer presented at the 2024 Gastrointestinal Cancers Symposium
    • 12 Aug 2023 Status changed from recruiting to active, no longer recruiting.
    • 22 Mar 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top